Amgen, Inc. (NASDAQ:AMGN) a biotechnology company, said Friday it has filed a lawsuit in the U.S. District Court of Delaware against Sanofi (SNY), Aventisub LLC, formerly doing business as Aventis Pharmaceuticals Inc. and Regeneron Pharmaceuticals (REGN) for patent infringement of AMGN's patent related to monoclonal antibodies to proprotein convertase subtilisin/kexin type 9. AMGN seeks an injunction to prevent the infringing manufacture, use and sale of Sanofi and Regeneron's alirocumab, a monoclonal antibody targeting PCSK9. Sanofi and Regeneron recently announced they have completed Phase 3 clinical trials on alirocumab and intend to pursue regulatory approval to market alirocumab in the U.S.Amgen, Inc. (NASDAQ:AMGN) previously announced submission of a Biologics License Application to the U.S. Food and Drug Administration for evolocumab, its own investigational human monoclonal antibody to PCSK9, for the treatment of high cholesterol, on Aug. 28, 2014. Shortly after Friday's open, AMGN shares were down 0.4% at $129.88, in a 52-week range of $108.20 to $144.46. SNY was up 1.4% at $51.36, and REGN shares were up 9.2% at $372.13. REGN's jump came after the company said Friday an independent study found its Eyelea injection to treat diabetic macular edema showed a greater improvement in vision at 52 weeks compared with rival Genentech's Avastin and LucentisShares of e-commerce company Zulily Inc (NASDAQ:ZU) rose in Friday's pre-market session, after Canaccord Genuity initiated coverage of the stock with a buy investment rating and a $45 target price, describing the company as offering "inspirational shopping for moms." The target price is 20% above the stock's Thursday closing price of $37.45. Since its public debut in November 2013, Zulily Inc (NASDAQ:ZU) has traded in a range of $28.75 to $73.50.Covidien plc (NYSE:COV) said it has been granted an injunction by the U.S. District Court of Connecticut against Johnson & Johnson (JNJ) unit, Ethicon Endo-Surgery, in a lawsuit related to the infringement of three of its patents. The lawsuit was filed by Covidien in June 2014 and alleges Ethicon's latest ultrasonic surgical product, the Harmonic ACE+7, infringes its patents. The injunction prevents Ethicon from manufacturing, marketing and selling the Harmonic ACE+7. Covidien plc (NYSE:COV) said Ethicon's Harmonic devices were found to infringe the same patents in a prior suit in the same court that resulted in a damages award against Ethicon of more than $175 million, a finding that is currently under appeal. Covidien shares are trading with a 52-week range of $60.71 - $95.29. JNJ has a range of $86.09 - $108.77.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
